StreetInsider.com News Articles

Artiva plans Phase 3 trial and data updates for AlloNK in 2026

Tue, 08 Sep 2026 07:30:47 -0400

Artiva Biotherapeutics (Nasdaq: ARTV) announced plans to initiate a Phase 3 randomized controlled trial evaluating its lead therapy AlloNK plus rituximab versus rituximab alone in approximately 150 patients with refractory rheumatoid arthritis (RA), according to a company statement.

The trial will enroll patients who have had an inadequate response to at least two distinct classes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs. The primary efficacy endpoint is ACR50 response at six months, with topline results expected by the end of 2028. The company said it has alignment with the FDA to conduct a single registrational trial.

Artiva also said it expects

Artiva plans Phase 3 trial and data updates for AlloNK in 2026

Tue, 08 Sep 2026 07:30:47 -0400

Artiva also said it expects

Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026

Tue, 08 Sep 2026 07:30:00 -0400

Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2a basket trial, each with at least six months of follow-up, including at least 10 patients who would meet key eligibility criteria for the Phase 3 registrational trial in refractory RA

Updated clinical data expected in the second half of 2026 from at least 10 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc), each with at least six months of follow-up

Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026

Tue, 08 Sep 2026 07:30:00 -0400

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September

Wed, 02 Sep 2026 08:30:00 -0400

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate at the following investor conferences:

2026 Cantor Global Healthcare Conference – live fireside chat on Wednesday, September 9, 2026 at 10:20 am EDT
H.C. Wainwright 28th Annual Global Investment Conference – live fireside chat on Monday, September 14, 2026 at 2:30 pm EDT

The Artiva management team will

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September

Wed, 02 Sep 2026 08:30:00 -0400

2026 Cantor Global Healthcare Conference – live fireside chat on Wednesday, September 9, 2026 at 10:20 am EDT
H.C. Wainwright 28th Annual Global Investment Conference – live fireside chat on Monday, September 14, 2026 at 2:30 pm EDT

The Artiva management team will

Form 144 Artiva Biotherapeutics, Filed by: Banerjee Subhashis

Thu, 27 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260827/26990286.html

Form 144 Artiva Biotherapeutics, Filed by: Banerjee Subhashis

Thu, 27 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260827/26990286.html

Form 4 Artiva Biotherapeutics, For: Aug 18 Filed by: Banerjee Subhashis

Wed, 19 Aug 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26951665.html

Form 4 Artiva Biotherapeutics, For: Aug 18 Filed by: Banerjee Subhashis

Wed, 19 Aug 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26951665.html

Form 144 Artiva Biotherapeutics, Filed by: Banerjee Subhashis

Tue, 18 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26944787.html

Form 144 Artiva Biotherapeutics, Filed by: Banerjee Subhashis

Tue, 18 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26944787.html

Form EFFECT Artiva Biotherapeutics,

Mon, 17 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26934372.html

Form EFFECT Artiva Biotherapeutics,

Mon, 17 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26934372.html

Form SCHEDULE 13G/A Artiva Biotherapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932217.html

Form SCHEDULE 13G/A Artiva Biotherapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26932217.html

Form SCHEDULE 13G/A Artiva Biotherapeutics, Filed by: 5AM Ventures VI, L.P.

Mon, 10 Aug 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260810/26899618.html

Form SCHEDULE 13G/A Artiva Biotherapeutics, Filed by: 5AM Ventures VI, L.P.

Mon, 10 Aug 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260810/26899618.html

Artiva Biotherapeutics, Inc. (ARTV) Misses Q2 EPS by 63c

Fri, 07 Aug 2026 16:23:27 -0400

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) reported Q2 EPS of ($0.63), $0.63 worse than the analyst estimate of $0.00.

For earnings history and earnings-related data on Artiva Biotherapeutics, Inc. (ARTV) click here.

Form S-3 Artiva Biotherapeutics,

Thu, 06 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260806/26885625.html

Form S-3 Artiva Biotherapeutics,

Thu, 06 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260806/26885625.html

Form 10-Q Artiva Biotherapeutics, For: Jun 30

Thu, 06 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260806/26884155.html

Form 10-Q Artiva Biotherapeutics, For: Jun 30

Thu, 06 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260806/26884155.html

Form 8-K Artiva Biotherapeutics, For: Aug 06

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883896.html

Form 8-K Artiva Biotherapeutics, For: Aug 06

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883896.html